NPI: 1952347791 · MARLBOROUGH, MA 01752 · Clinical Medical Laboratory · NPI assigned 06/21/2006
Authorized official BOWLES, CHARLES controls 20+ related entities in our dataset. Read more
| Authorized Official | BOWLES, CHARLES (SR. VICE PRESIDENT) |
| Parent Organization | QUEST DIAGNOSTICS INCORPORATED |
| NPI Enumeration Date | 06/21/2006 |
Other providers sharing the same authorized official: BOWLES, CHARLES
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 5,614,562 | $21.32M |
| 2019 | 5,998,339 | $22.74M |
| 2020 | 5,287,200 | $25.74M |
| 2021 | 8,033,818 | $38.58M |
| 2022 | 6,632,039 | $34.06M |
| 2023 | 7,742,164 | $34.95M |
| 2024 | 6,630,328 | $32.35M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1,204,524 | 683,750 | $33.04M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 577,385 | 446,990 | $30.13M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 950,705 | 553,557 | $19.18M |
| 81513 | 82,909 | 77,648 | $7.07M | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 522,089 | 474,149 | $5.96M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 521,951 | 473,997 | $5.96M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 526,494 | 492,546 | $5.29M |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 519,853 | 486,690 | $5.23M |
| 86480 | 134,364 | 126,179 | $4.47M | |
| 84443 | Thyroid stimulating hormone (TSH) | 1,084,291 | 1,008,072 | $4.16M |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 90,625 | 84,449 | $4.02M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 200,840 | 184,638 | $3.70M |
| 83036 | Hemoglobin; glycosylated (A1C) | 866,443 | 809,696 | $3.26M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1,310,635 | 1,193,182 | $2.63M |
| 86003 | 57,555 | 51,142 | $2.53M | |
| 86803 | 401,876 | 375,138 | $2.31M | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 118,978 | 111,207 | $2.22M |
| 36415 | Collection of venous blood by venipuncture | 2,375,818 | 2,112,701 | $2.15M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 152,904 | 143,441 | $2.12M |
| 83013 | 57,995 | 54,358 | $2.02M | |
| 82607 | 342,851 | 320,487 | $1.71M | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 376,535 | 340,060 | $1.52M |
| 86780 | 220,394 | 206,655 | $1.45M | |
| 87522 | Neg quan hep c or qual rna | 57,950 | 53,600 | $1.36M |
| 83718 | 1,057,543 | 989,398 | $1.33M | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 11,106 | 9,761 | $1.18M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 56,908 | 52,610 | $1.17M |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 2,051 | 1,987 | $1.15M |
| 82465 | 1,069,582 | 1,000,704 | $1.10M | |
| 84478 | 1,055,544 | 985,020 | $1.09M | |
| 84439 | 259,863 | 241,073 | $1.08M | |
| 87340 | 240,774 | 225,865 | $1.04M | |
| 87070 | 217,122 | 198,550 | $1.03M | |
| 82728 | 290,729 | 270,336 | $974K | |
| 82746 | 222,503 | 208,168 | $944K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3,439 | 3,227 | $811K |
| 85027 | 383,506 | 355,247 | $776K | |
| 87536 | 25,613 | 24,025 | $758K | |
| 86235 | 27,064 | 25,033 | $742K | |
| 87088 | 290,269 | 263,002 | $739K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 28,427 | 24,352 | $724K |
| 80061 | Lipid panel | 131,613 | 120,612 | $700K |
| 80050 | General health panel | 36,044 | 32,910 | $681K |
| 84153 | 119,373 | 111,574 | $666K | |
| 81001 | 410,750 | 380,138 | $661K | |
| 83655 | 148,535 | 139,256 | $645K | |
| 86769 | 16,377 | 15,191 | $619K | |
| 83550 | 270,790 | 251,911 | $609K | |
| 80053 | Comprehensive metabolic panel | 154,932 | 139,169 | $596K |
| 83540 | 295,312 | 274,738 | $518K | |
| 82565 | 1,533,961 | 1,400,834 | $504K | |
| 87186 | 119,642 | 109,302 | $493K | |
| 84702 | 68,438 | 53,287 | $470K | |
| 87631 | 6,131 | 5,783 | $459K | |
| 86317 | 78,469 | 73,817 | $455K | |
| 83970 | 47,480 | 44,248 | $447K | |
| 86704 | 76,949 | 72,358 | $443K | |
| 84450 | 1,436,398 | 1,317,993 | $437K | |
| 86705 | 71,637 | 67,703 | $437K | |
| 82310 | 1,503,281 | 1,373,801 | $425K | |
| 82043 | 171,751 | 160,591 | $425K | |
| 86709 | 73,019 | 69,009 | $416K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4,647 | 3,191 | $416K |
| 86618 | 66,714 | 62,687 | $415K | |
| 87077 | 139,766 | 127,896 | $413K | |
| 82947 | 1,519,576 | 1,389,981 | $405K | |
| 84460 | 1,441,147 | 1,322,224 | $405K | |
| 84295 | 1,497,633 | 1,369,567 | $404K | |
| 86592 | 200,801 | 188,624 | $403K | |
| 88142 | 34,374 | 32,096 | $401K | |
| 87480 | 35,864 | 33,232 | $393K | |
| 87510 | 35,859 | 33,230 | $391K | |
| 82374 | 1,496,126 | 1,368,403 | $390K | |
| 84520 | 1,518,788 | 1,387,545 | $388K | |
| 84132 | 1,498,943 | 1,370,488 | $383K | |
| 86038 | 100,724 | 92,907 | $375K | |
| 82670 | 31,641 | 29,376 | $375K | |
| 87660 | 35,839 | 33,217 | $374K | |
| 82435 | 1,496,142 | 1,368,400 | $373K | |
| 86140 | 145,682 | 130,740 | $370K | |
| 84075 | 1,385,760 | 1,271,895 | $365K | |
| 82247 | 1,383,163 | 1,269,447 | $363K | |
| 82105 | 46,113 | 43,097 | $362K | |
| 82040 | 1,405,419 | 1,288,888 | $359K | |
| 82784 | 68,553 | 63,784 | $353K | |
| 86617 | 25,825 | 24,075 | $346K | |
| 82570 | 265,566 | 217,602 | $341K | |
| 86706 | 65,620 | 61,613 | $338K | |
| 86708 | 59,651 | 55,987 | $336K | |
| 87081 | 87,602 | 81,143 | $326K | |
| 83525 | 58,861 | 55,294 | $325K | |
| 83516 | 37,028 | 33,683 | $322K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 9,053 | 8,191 | $308K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 7,972 | 7,594 | $305K |
| 84146 | 50,529 | 47,133 | $296K | |
| 84155 | 1,389,689 | 1,275,141 | $286K | |
| 83001 | 44,889 | 41,886 | $284K | |
| 86376 | 46,118 | 42,991 | $276K | |
| 87902 | 2,934 | 2,668 | $272K | |
| 83735 | 101,035 | 85,059 | $267K | |
| 86666 | 19,841 | 14,360 | $266K | |
| 86762 | 64,558 | 60,820 | $262K | |
| 88112 | 11,149 | 9,961 | $254K | |
| 82785 | 38,612 | 36,510 | $240K | |
| 85652 | 176,836 | 161,103 | $239K | |
| 84481 | 45,775 | 42,366 | $235K | |
| 84403 | 25,034 | 23,313 | $232K | |
| 86800 | 38,749 | 35,971 | $228K | |
| 83002 | 36,788 | 34,430 | $224K | |
| 86364 | 28,745 | 27,247 | $223K | |
| 86008 | 10,110 | 8,660 | $218K | |
| 86787 | 48,155 | 45,165 | $216K | |
| 80081 | 4,599 | 3,943 | $215K | |
| 86200 | 38,586 | 36,251 | $203K | |
| 86665 | 15,510 | 14,321 | $200K | |
| 84480 | 44,299 | 41,280 | $186K | |
| 83020 | 20,660 | 19,023 | $184K | |
| 87147 | 47,197 | 43,825 | $177K | |
| 86696 | 34,203 | 32,172 | $171K | |
| 82627 | 24,712 | 23,103 | $169K | |
| 86160 | 16,139 | 15,040 | $163K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 3,334 | 2,691 | $162K |
| 84436 | 65,867 | 61,828 | $159K | |
| 86765 | 39,079 | 36,832 | $159K | |
| 83880 | 13,123 | 11,877 | $156K | |
| 86735 | 36,820 | 34,685 | $152K | |
| 86360 | 11,471 | 10,823 | $148K | |
| 82533 | 20,881 | 19,075 | $148K | |
| 83690 | 46,847 | 43,152 | $147K | |
| 86431 | 59,588 | 55,917 | $136K | |
| 85610 | 71,582 | 61,023 | $135K | |
| 88141 | 15,906 | 14,721 | $134K | |
| 82274 | 19,500 | 18,218 | $132K | |
| 80074 | 5,764 | 5,198 | $130K | |
| 86753 | 14,597 | 12,959 | $129K | |
| 83021 | 14,107 | 13,802 | $128K | |
| 80164 | 22,814 | 20,726 | $126K | |
| 87517 | 5,360 | 5,050 | $123K | |
| 86039 | 27,282 | 25,506 | $119K | |
| 82550 | 37,443 | 34,121 | $119K | |
| 86225 | 22,887 | 21,505 | $118K | |
| 81401 | 852 | 835 | $112K | |
| 86695 | 31,131 | 29,304 | $112K | |
| 80197 | 20,696 | 13,338 | $111K | |
| 83721 | 29,723 | 27,938 | $110K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 3,784 | 2,603 | $109K |
| 84144 | 12,715 | 11,380 | $107K | |
| 88304 | 7,794 | 7,368 | $107K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1,414 | 1,370 | $106K |
| 84479 | 42,891 | 40,386 | $106K | |
| 87506 | 933 | 868 | $106K | |
| 86361 | 9,846 | 9,271 | $104K | |
| 85730 | 36,752 | 34,227 | $102K | |
| 84703 | 25,888 | 24,043 | $102K | |
| 82330 | 20,606 | 19,222 | $102K | |
| 88342 | 3,102 | 2,532 | $102K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 2,253 | 1,125 | $97K |
| 86141 | 15,526 | 14,310 | $95K | |
| 84270 | 11,684 | 10,915 | $94K | |
| 83014 | 22,568 | 21,128 | $93K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 27,950 | 23,736 | $92K |
| 86850 | 35,964 | 33,898 | $91K | |
| 87338 | 11,579 | 10,799 | $90K | |
| 82248 | 158,730 | 145,005 | $89K | |
| 82150 | 26,834 | 24,709 | $89K | |
| 87209 | 15,664 | 14,268 | $88K | |
| 84550 | 63,851 | 59,482 | $88K | |
| 86334 | 9,912 | 9,253 | $86K | |
| 87427 | 14,170 | 13,111 | $85K | |
| 87799 | 5,804 | 3,077 | $84K | |
| 86258 | 7,302 | 6,929 | $82K | |
| 87625 | 4,810 | 4,542 | $81K | |
| 87449 | 16,281 | 12,745 | $78K | |
| 86664 | 13,442 | 12,419 | $78K | |
| 85018 | 96,058 | 90,164 | $77K | |
| 88341 | 1,679 | 1,452 | $77K | |
| 82950 | 33,267 | 30,918 | $76K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 305 | 292 | $76K |
| 82652 | 3,573 | 3,325 | $75K | |
| 87045 | 14,886 | 13,770 | $74K | |
| 84154 | 18,840 | 17,705 | $73K | |
| 84165 | 17,602 | 16,325 | $73K | |
| 87329 | 12,419 | 11,274 | $72K | |
| 80178 | 21,612 | 18,959 | $69K | |
| 85014 | 83,176 | 77,998 | $67K | |
| 84156 | 41,334 | 36,212 | $66K | |
| 84681 | 9,014 | 8,425 | $66K | |
| 82977 | 35,106 | 32,101 | $65K | |
| 84466 | 10,134 | 9,457 | $64K | |
| 84402 | 4,021 | 3,886 | $63K | |
| 86901 | 39,379 | 36,886 | $63K | |
| 86900 | 39,484 | 36,996 | $62K | |
| 87493 | 3,558 | 3,320 | $61K | |
| 84100 | 78,183 | 65,602 | $61K | |
| 81003 | 54,556 | 51,125 | $60K | |
| 87205 | 25,206 | 23,243 | $59K | |
| 87075 | 11,316 | 10,410 | $59K | |
| 87177 | 15,665 | 14,267 | $59K | |
| 85007 | 39,546 | 36,278 | $59K | |
| 83520 | 8,907 | 6,103 | $59K | |
| 86747 | 5,135 | 4,720 | $58K | |
| 86147 | 5,093 | 4,579 | $58K | |
| 88185 | 238 | 226 | $56K | |
| 82024 | 5,242 | 4,789 | $56K | |
| 83615 | 30,526 | 27,079 | $55K | |
| 87324 | 10,193 | 9,308 | $53K | |
| 86870 | 2,276 | 2,058 | $53K | |
| 81329 | 1,424 | 1,388 | $50K | |
| 82951 | 8,060 | 7,561 | $50K | |
| 83090 | 8,258 | 7,784 | $49K | |
| 80076 | 10,472 | 9,430 | $48K | |
| 86021 | 5,024 | 4,648 | $48K | |
| 87150 | 2,296 | 2,177 | $45K | |
| 85045 | 21,005 | 19,405 | $44K | |
| 87254 | 5,506 | 5,332 | $42K | |
| 88230 | 930 | 883 | $40K | |
| 82378 | 5,584 | 4,809 | $39K | |
| 85041 | 38,548 | 35,963 | $39K | |
| 81596 | 1,404 | 1,327 | $37K | |
| 87497 | 2,011 | 1,185 | $37K | |
| 82390 | 7,517 | 7,072 | $37K | |
| 86304 | 3,842 | 3,488 | $35K | |
| 86777 | 4,891 | 4,627 | $35K | |
| 87046 | 10,659 | 8,988 | $35K | |
| 84134 | 8,656 | 7,335 | $35K | |
| 87102 | 6,313 | 5,878 | $35K | |
| 86644 | 5,045 | 4,717 | $34K | |
| 81025 | 9,760 | 8,480 | $34K | |
| 87650 | 2,695 | 2,499 | $33K | |
| 86255 | 5,880 | 4,026 | $32K | |
| 88262 | 662 | 626 | $32K | |
| 85379 | 6,227 | 5,742 | $32K | |
| 82747 | 5,596 | 5,348 | $32K | |
| 83521 | 3,549 | 3,348 | $31K | |
| 84425 | 3,109 | 3,024 | $31K | |
| 87255 | 2,887 | 2,466 | $28K | |
| 88344 | 506 | 441 | $28K | |
| 82677 | 2,314 | 2,214 | $26K | |
| 85048 | 25,061 | 22,924 | $26K | |
| 86778 | 3,457 | 3,275 | $25K | |
| 88300 | 3,794 | 3,628 | $25K | |
| 85060 | 3,673 | 3,387 | $25K | |
| 80055 | 828 | 754 | $24K | |
| 87101 | 4,753 | 4,459 | $24K | |
| 82787 | 2,070 | 1,873 | $24K | |
| 86593 | 11,318 | 10,464 | $23K | |
| 86308 | 7,933 | 7,425 | $23K | |
| 86645 | 4,365 | 4,075 | $23K | |
| 86301 | 3,052 | 2,650 | $23K | |
| 84166 | 3,094 | 2,827 | $23K | |
| 87106 | 4,290 | 3,979 | $22K | |
| 87484 | 1,561 | 1,442 | $22K | |
| 82103 | 4,737 | 4,465 | $21K | |
| 86060 | 5,689 | 5,357 | $21K | |
| 83010 | 3,706 | 3,472 | $21K | |
| 84432 | 3,863 | 3,552 | $21K | |
| 86359 | 3,950 | 3,742 | $21K | |
| 82668 | 2,093 | 1,992 | $19K | |
| 87206 | 5,599 | 5,076 | $19K | |
| 86702 | 2,695 | 2,467 | $19K | |
| 86381 | 2,546 | 2,441 | $17K | |
| 86336 | 2,306 | 2,206 | $17K | |
| 87469 | 2,173 | 2,022 | $16K | |
| 80156 | 3,050 | 2,832 | $16K | |
| 85660 | 5,845 | 5,516 | $16K | |
| 85246 | 1,658 | 1,542 | $15K | |
| 87468 | 1,658 | 1,535 | $15K | |
| 87040 | 2,660 | 2,142 | $15K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 19,970 | 16,130 | $14K |
| 86036 | 1,980 | 1,901 | $14K | |
| 86663 | 2,588 | 2,443 | $14K | |
| 85613 | 2,874 | 2,705 | $14K | |
| 86015 | 2,616 | 2,485 | $14K | |
| 88312 | 497 | 460 | $13K | |
| 81015 | 8,715 | 8,229 | $13K | |
| 82952 | 6,357 | 5,954 | $13K | |
| 80185 | 2,322 | 2,088 | $12K | |
| 86335 | 1,317 | 1,247 | $12K | |
| 86701 | 2,695 | 2,467 | $12K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1,039 | 1,021 | $12K |
| 87350 | 1,971 | 1,864 | $12K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 184 | 176 | $12K |
| 83921 | 1,494 | 1,439 | $12K | |
| 86707 | 1,767 | 1,675 | $11K | |
| 87512 | 1,779 | 1,624 | $11K | |
| 87140 | 2,756 | 2,403 | $11K | |
| ATP03 | 2,427 | 2,406 | $10K | |
| 85245 | 1,230 | 1,169 | $10K | |
| ATP14 | 6,231 | 5,956 | $10K | |
| 84630 | 1,432 | 1,356 | $10K | |
| 84484 | 1,807 | 1,594 | $9K | |
| ATP17 | 4,671 | 4,647 | $9K | |
| 84207 | 713 | 682 | $9K | |
| 87220 | 2,729 | 2,601 | $8K | |
| 80159 | 1,488 | 1,154 | $8K | |
| 80051 | 2,279 | 1,967 | $8K | |
| 87076 | 1,591 | 1,511 | $7K | |
| 85240 | 925 | 867 | $7K | |
| 83883 | 1,653 | 920 | $7K | |
| 83935 | 2,158 | 1,934 | $7K | |
| 86300 | 1,026 | 896 | $7K | |
| 80069 | 1,921 | 1,650 | $7K | |
| 80202 | 1,079 | 611 | $7K | |
| ATP15 | 2,437 | 1,916 | $7K | |
| 85004 | 4,527 | 4,032 | $7K | |
| 82232 | 992 | 932 | $7K | |
| 83498 | 308 | 305 | $6K | |
| 87275 | 902 | 881 | $6K | |
| 82525 | 806 | 766 | $6K | |
| 87276 | 902 | 881 | $6K | |
| 83930 | 2,078 | 1,859 | $6K | |
| 87328 | 924 | 840 | $6K | |
| 87481 | 480 | 348 | $6K | |
| 87529 | 526 | 256 | $6K | |
| 88189 | 182 | 172 | $6K | |
| 81511 | 788 | 737 | $6K | |
| 87107 | 807 | 773 | $5K | |
| 84445 | 168 | 164 | $5K | |
| 84300 | 2,274 | 2,055 | $5K | |
| 87272 | 843 | 818 | $5K | |
| 88184 | 250 | 238 | $5K | |
| 88271 | 79 | 74 | $5K | |
| 80158 | 763 | 484 | $5K | |
| 86886 | 1,663 | 1,509 | $5K | |
| 88307 | 78 | 76 | $5K | |
| 82340 | 1,901 | 1,766 | $5K | |
| 86146 | 256 | 133 | $5K | |
| 82542 | 343 | 295 | $5K | |
| 88313 | 121 | 114 | $4K | |
| 85384 | 919 | 845 | $4K | |
| 84255 | 215 | 212 | $4K | |
| 82140 | 558 | 491 | $4K | |
| 87207 | 1,147 | 1,082 | $4K | |
| ATP16 | 1,209 | 798 | $4K | |
| 85306 | 451 | 441 | $4K | |
| 80195 | 624 | 455 | $4K | |
| ATP09 | 2,452 | 1,753 | $3K | |
| ATP08 | 2,205 | 2,081 | $3K | |
| 80184 | 786 | 734 | $3K | |
| 85300 | 557 | 522 | $3K | |
| 82672 | 194 | 188 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 291 | 282 | $3K |
| 81229 | 92 | 80 | $3K | |
| 83003 | 483 | 394 | $3K | |
| 89055 | 1,263 | 1,139 | $3K | |
| 86341 | 84 | 70 | $3K | |
| 85303 | 375 | 359 | $2K | |
| 82985 | 679 | 649 | $2K | |
| 80177 | 513 | 492 | $2K | |
| 87800 | 32 | 26 | $2K | |
| 87478 | 335 | 310 | $2K | |
| 80299 | 273 | 249 | $2K | |
| 85049 | 2,140 | 1,989 | $2K | |
| 84482 | 208 | 188 | $2K | |
| 87300 | 222 | 218 | $2K | |
| 82553 | 438 | 385 | $2K | |
| 87280 | 253 | 217 | $2K | |
| 87015 | 487 | 444 | $2K | |
| 86880 | 567 | 516 | $2K | |
| 86256 | 245 | 220 | $1K | |
| 84305 | 113 | 113 | $1K | |
| 88235 | 15 | 12 | $1K | |
| 82172 | 338 | 323 | $1K | |
| 82610 | 298 | 185 | $1K | |
| 83993 | 129 | 127 | $1K | |
| 80175 | 283 | 271 | $1K | |
| 80162 | 240 | 210 | $1K | |
| 86628 | 55 | 52 | $1K | |
| ATP04 | 236 | 228 | $1K | |
| ATP07 | 448 | 437 | $963.73 | |
| 86812 | 79 | 74 | $907.14 | |
| 83695 | 110 | 107 | $829.88 | |
| ATP02 | 359 | 353 | $818.42 | |
| 81243 | 16 | 16 | $785.02 | |
| 86611 | 56 | 43 | $783.84 | |
| 80165 | 3,263 | 2,971 | $694.36 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 450 | 446 | $660.92 |
| 83519 | 96 | 65 | $644.97 | |
| 84590 | 114 | 109 | $635.65 | |
| 87563 | 39 | 37 | $624.89 | |
| 82104 | 71 | 70 | $572.70 | |
| 87185 | 454 | 432 | $509.24 | |
| 89060 | 124 | 118 | $495.40 | |
| 89051 | 168 | 160 | $490.17 | |
| 86905 | 194 | 181 | $479.22 | |
| ATP11 | 198 | 197 | $464.72 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 2,165 | 2,133 | $464.51 |
| ATP10 | 146 | 141 | $379.39 | |
| 85597 | 58 | 56 | $368.39 | |
| 86337 | 30 | 29 | $365.30 | |
| 82530 | 28 | 25 | $351.99 | |
| ATP05 | 86 | 86 | $350.07 | |
| 81256 | 245 | 234 | $340.42 | |
| 82088 | 12 | 12 | $335.51 | |
| 87116 | 68 | 56 | $334.43 | |
| ATP18 | 148 | 148 | $320.61 | |
| 81241 | 763 | 736 | $269.39 | |
| 87172 | 92 | 43 | $264.69 | |
| 81240 | 417 | 405 | $178.50 | |
| 82575 | 25 | 24 | $144.00 | |
| 88302 | 14 | 14 | $141.48 | |
| 87260 | 13 | 12 | $122.99 | |
| 83835 | 13 | 12 | $111.87 | |
| 86037 | 14 | 14 | $111.85 | |
| 81291 | 565 | 543 | $111.74 | |
| 82552 | 13 | 13 | $85.35 | |
| 84133 | 42 | 39 | $85.05 | |
| 99001 | 154 | 115 | $83.64 | |
| 80183 | 14 | 13 | $77.43 | |
| 86632 | 13 | 12 | $72.97 | |
| 84560 | 27 | 24 | $70.91 | |
| 85598 | 12 | 12 | $60.36 | |
| ATP13 | 13 | 13 | $55.20 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 363 | 360 | $46.35 |
| 36416 | 378 | 330 | $35.00 | |
| 80349 | 130 | 75 | $0.00 | |
| 80358 | 268 | 127 | $0.00 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | 274 | 272 | $0.00 |
| G0434 | Drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter | 426 | 251 | $0.00 |
| 80354 | 322 | 154 | $0.00 | |
| 80348 | 46 | 26 | $0.00 |